Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 1.34 Vs. IBES Estimate USD 1.09
08/11/2024 11:51
Nov 08 (Reuters) - ANI Pharmaceuticals Q3 revenue USD 148.332 million vs. IBES estimate USD 144.4 million. * outlook FY adjusted EPS USD 4.9-5.05 * outlook FY adjusted EBITDA USD 149-153 million
Recent news on ANI Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma